$CYRX
Cryoport, Inc.

2013 Q3 Form 10-Q Financial Statement

#000114420413062580 Filed on November 18, 2013

View on sec.gov

Income Statement

Concept 2013 Q3 2012 Q3
Revenue $580.0K $234.0K
YoY Change 147.86% 112.73%
Cost Of Revenue $507.7K $344.4K
YoY Change 47.41% -4.32%
Gross Profit $72.00K -$111.0K
YoY Change -164.86% -55.6%
Gross Profit Margin 12.41% -47.44%
Selling, General & Admin $1.240M $1.341M
YoY Change -7.52% -14.02%
% of Gross Profit 1722.8%
Research & Development $118.4K $101.7K
YoY Change 16.51% -15.29%
% of Gross Profit 164.49%
Depreciation & Amortization $61.82K $92.71K
YoY Change -33.31% 15.88%
% of Gross Profit 85.87%
Operating Expenses $1.359M $1.443M
YoY Change -5.83% -14.62%
Operating Profit -$1.287M -$1.554M
YoY Change -17.18% -19.9%
Interest Expense $512.8K $11.76K
YoY Change 4260.71% -113.07%
% of Operating Profit
Other Income/Expense, Net $0.00 $2.730K
YoY Change -100.0%
Pretax Income -$14.96M -$1.551M
YoY Change 864.45% -23.59%
Income Tax $0.00 $1.600K
% Of Pretax Income
Net Earnings -$14.96M -$1.551M
YoY Change 864.54% -23.6%
Net Earnings / Revenue -2579.31% -662.82%
Basic Earnings Per Share
Diluted Earnings Per Share -$4.589M -$492.1K
COMMON SHARES
Basic Shares Outstanding 38.26M shares
Diluted Shares Outstanding 40.52M shares 37.76M shares

Balance Sheet

Concept 2013 Q3 2012 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $500.0K $1.700M
YoY Change -70.59% -66.0%
Cash & Equivalents $532.5K $1.670M
Short-Term Investments
Other Short-Term Assets $40.69K $0.00
YoY Change -100.0%
Inventory $43.31K $100.0K
Prepaid Expenses
Receivables $387.7K $200.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $1.004M $1.900M
YoY Change -47.15% -64.81%
LONG-TERM ASSETS
Property, Plant & Equipment $516.6K $600.0K
YoY Change -13.9% -14.29%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change
Total Long-Term Assets $753.2K $900.0K
YoY Change -16.31% -10.0%
TOTAL ASSETS
Total Short-Term Assets $1.004M $1.900M
Total Long-Term Assets $753.2K $900.0K
Total Assets $1.757M $2.800M
YoY Change -37.24% -56.25%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $600.0K $500.0K
YoY Change 20.0% -16.67%
Accrued Expenses $300.0K $100.0K
YoY Change 200.0% -75.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $100.0K $100.0K
YoY Change 0.0% -92.86%
Total Short-Term Liabilities $1.043M $700.0K
YoY Change 48.94% -72.0%
LONG-TERM LIABILITIES
Long-Term Debt $1.300M $1.300M
YoY Change 0.0% -7.14%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $1.300M $1.300M
YoY Change 0.0% -7.14%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.043M $700.0K
Total Long-Term Liabilities $1.300M $1.300M
Total Liabilities $2.335M $2.100M
YoY Change 11.2% -46.15%
SHAREHOLDERS EQUITY
Retained Earnings -$82.59M
YoY Change
Common Stock $82.02M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$577.9K $800.0K
YoY Change
Total Liabilities & Shareholders Equity $1.757M $2.800M
YoY Change -37.24% -56.25%

Cashflow Statement

Concept 2013 Q3 2012 Q3
OPERATING ACTIVITIES
Net Income -$14.96M -$1.551M
YoY Change 864.54% -23.6%
Depreciation, Depletion And Amortization $61.82K $92.71K
YoY Change -33.31% 15.88%
Cash From Operating Activities -$1.150M -$1.240M
YoY Change -7.26% -24.39%
INVESTING ACTIVITIES
Capital Expenditures -$10.00K -$10.00K
YoY Change 0.0% -92.31%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K -$10.00K
YoY Change 0.0% -92.31%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.450M -70.00K
YoY Change -2171.43% -78.13%
NET CHANGE
Cash From Operating Activities -1.150M -1.240M
Cash From Investing Activities -10.00K -10.00K
Cash From Financing Activities 1.450M -70.00K
Net Change In Cash 290.0K -1.320M
YoY Change -121.97% -36.84%
FREE CASH FLOW
Cash From Operating Activities -$1.150M -$1.240M
Capital Expenditures -$10.00K -$10.00K
Free Cash Flow -$1.140M -$1.230M
YoY Change -7.32% -18.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
505485 USD
CY2013Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
216817 USD
CY2013Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
217097 USD
CY2013Q3 us-gaap Inventory Net
InventoryNet
43305 USD
CY2013Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
16800 USD
CY2013Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
272263 USD
CY2013Q3 cyrx Depositsandotherassets
Depositsandotherassets
19744 USD
CY2013Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
8700 USD
CY2013Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
58146502 shares
CY2013Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
37760628 shares
CY2013Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
37760628 shares
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
532469 USD
CY2013Q1 us-gaap Inventory Net
InventoryNet
39212 USD
CY2013Q3 us-gaap Other Assets Current
OtherAssetsCurrent
40685 USD
CY2013Q1 us-gaap Other Assets Current
OtherAssetsCurrent
138892 USD
CY2013Q3 us-gaap Assets Current
AssetsCurrent
1004128 USD
CY2013Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2013Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2500000 shares
CY2013Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2013Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
58146502 shares
CY2013Q3 us-gaap Assets
Assets
1757317 USD
CY2013Q1 us-gaap Assets
Assets
1755797 USD
CY2013Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
602957 USD
CY2013Q1 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
858709 USD
CY2013Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
342427 USD
CY2013Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
217432 USD
CY2013Q3 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
0 USD
CY2013Q1 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
1304419 USD
CY2013Q1 us-gaap Assets Current
AssetsCurrent
958305 USD
CY2013Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
516628 USD
CY2013Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
563104 USD
CY2013Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
387669 USD
us-gaap Cost Of Revenue
CostOfRevenue
698058 USD
CY2012Q3 us-gaap Gross Profit
GrossProfit
-110843 USD
us-gaap Gross Profit
GrossProfit
126744 USD
us-gaap Operating Expenses
OperatingExpenses
2673566 USD
us-gaap Operating Expenses
OperatingExpenses
2821214 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1286747 USD
CY2012Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1553832 USD
CY2012Q3 us-gaap Sales Revenue Net
SalesRevenueNet
233597 USD
us-gaap Sales Revenue Net
SalesRevenueNet
1067790 USD
CY2013Q3 us-gaap Cost Of Revenue
CostOfRevenue
507725 USD
CY2012Q3 us-gaap Operating Expenses
OperatingExpenses
1442989 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4093 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-221520 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
76403 USD
CY2013Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q3 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
96000 USD
CY2013Q1 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
96000 USD
CY2013Q3 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
1199 USD
CY2013Q1 us-gaap Derivative Instruments And Hedges Liabilities
DerivativeInstrumentsAndHedgesLiabilities
20848 USD
CY2013Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1042583 USD
CY2013Q1 us-gaap Liabilities Current
LiabilitiesCurrent
2497408 USD
CY2013Q3 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
1292612 USD
CY2013Q1 us-gaap Notes Payable Related Parties Noncurrent
NotesPayableRelatedPartiesNoncurrent
1321664 USD
CY2013Q3 us-gaap Liabilities
Liabilities
2335195 USD
CY2013Q1 us-gaap Liabilities
Liabilities
3819072 USD
CY2013Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q3 us-gaap Common Stock Value
CommonStockValue
58146 USD
CY2013Q1 us-gaap Common Stock Value
CommonStockValue
37761 USD
CY2013Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
81958609 USD
CY2013Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
64210412 USD
CY2013Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-82594633 USD
CY2013Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66311448 USD
CY2013Q3 us-gaap Stockholders Equity
StockholdersEquity
-577878 USD
CY2013Q1 us-gaap Stockholders Equity
StockholdersEquity
-2063275 USD
CY2013Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1757317 USD
CY2013Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1755797 USD
CY2013Q1 cyrx Depositsandotherassets
Depositsandotherassets
19744 USD
CY2013Q3 us-gaap Sales Revenue Net
SalesRevenueNet
579827 USD
us-gaap Sales Revenue Net
SalesRevenueNet
424896 USD
CY2012Q3 us-gaap Cost Of Revenue
CostOfRevenue
344440 USD
us-gaap Cost Of Revenue
CostOfRevenue
941046 USD
CY2013Q3 us-gaap Gross Profit
GrossProfit
72102 USD
us-gaap Gross Profit
GrossProfit
-273162 USD
CY2013Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1240413 USD
CY2012Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1341333 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2462487 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2610607 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
118436 USD
CY2012Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
101656 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
211079 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
210607 USD
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
1358849 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-2546822 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-3094376 USD
CY2013Q3 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
13161017 USD
CY2012Q3 us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0 USD
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
13161017 USD
us-gaap Induced Conversion Of Convertible Debt Expense
InducedConversionOfConvertibleDebtExpense
0 USD
CY2013Q3 us-gaap Interest Expense
InterestExpense
512776 USD
CY2012Q3 us-gaap Interest Expense
InterestExpense
11759 USD
us-gaap Interest Expense
InterestExpense
594995 USD
us-gaap Interest Expense
InterestExpense
36359 USD
CY2013Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
892 USD
CY2012Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
14489 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
19649 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
33824 USD
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13672901 USD
CY2012Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2730 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13736363 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2535 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-14959648 USD
CY2012Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-1551102 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-16283185 USD
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
9261 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
9627 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-27340 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3096911 USD
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2012Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1600 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1600 USD
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-2809 USD
us-gaap Disposal Group Not Discontinued Operation Gain Loss On Disposal
DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
-6382 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
170572 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
24244 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4165 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
78300 USD
cyrx Increase Decrease In Accrued Compensation And Related Expense
IncreaseDecreaseInAccruedCompensationAndRelatedExpense
-124995 USD
cyrx Increase Decrease In Accrued Compensation And Related Expense
IncreaseDecreaseInAccruedCompensationAndRelatedExpense
91208 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-14959648 USD
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-1552702 USD
us-gaap Net Income Loss
NetIncomeLoss
-16283185 USD
us-gaap Net Income Loss
NetIncomeLoss
-3098511 USD
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.38
CY2012Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.08
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
39110774 shares
CY2012Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37760628 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38589663 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
37760628 shares
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
178990 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
216931 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
515381 USD
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
8843 USD
cyrx Fair Value Of Stock Options And Warrants Issued To Consultants Employees And Directors
FairValueOfStockOptionsAndWarrantsIssuedToConsultantsEmployeesAndDirectors
-331220 USD
cyrx Fair Value Of Stock Options And Warrants Issued To Consultants Employees And Directors
FairValueOfStockOptionsAndWarrantsIssuedToConsultantsEmployeesAndDirectors
-249026 USD
us-gaap Unrealized Gain Loss On Derivatives And Commodity Contracts
UnrealizedGainLossOnDerivativesAndCommodityContracts
19649 USD
us-gaap Unrealized Gain Loss On Derivatives And Commodity Contracts
UnrealizedGainLossOnDerivativesAndCommodityContracts
33824 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2317831 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2655869 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
137496 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
46779 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-137496 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-46779 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2615301 USD
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0 USD
cyrx Repayments Of Convertible Debentures Payable
RepaymentsOfConvertibleDebenturesPayable
0 USD
cyrx Repayments Of Convertible Debentures Payable
RepaymentsOfConvertibleDebenturesPayable
82800 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
242609 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
122453 USD
cyrx Repayments Of Related Party Notes Payable
RepaymentsOfRelatedPartyNotesPayable
48000 USD
cyrx Repayments Of Related Party Notes Payable
RepaymentsOfRelatedPartyNotesPayable
40000 USD
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
100000 USD
us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2424692 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-245253 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-30635 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2947901 USD
CY2012Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4617535 USD
CY2012Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1669634 USD
us-gaap Interest Paid
InterestPaid
0 USD
us-gaap Interest Paid
InterestPaid
15676 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
0 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
1600 USD
cyrx Release Of Restricted Cash For Repayment Of Convertible Debentures Payable
ReleaseOfRestrictedCashForRepaymentOfConvertibleDebenturesPayable
0 USD
cyrx Release Of Restricted Cash For Repayment Of Convertible Debentures Payable
ReleaseOfRestrictedCashForRepaymentOfConvertibleDebenturesPayable
251368 USD
cyrx Deferred Financing Costs In Connection With Convertible Debt Payable Included In Accounts Payable
DeferredFinancingCostsInConnectionWithConvertibleDebtPayableIncludedInAccountsPayable
27743 USD
cyrx Deferred Financing Costs In Connection With Convertible Debt Payable Included In Accounts Payable
DeferredFinancingCostsInConnectionWithConvertibleDebtPayableIncludedInAccountsPayable
0 USD
cyrx Offering Costs In Connection With Equity Financing Included In Accounts Payable
OfferingCostsInConnectionWithEquityFinancingIncludedInAccountsPayable
0 USD
cyrx Offering Costs In Connection With Equity Financing Included In Accounts Payable
OfferingCostsInConnectionWithEquityFinancingIncludedInAccountsPayable
59569 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
3977175 USD
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
0 USD
cyrx Debt Conversion Converted Instrument Amount Warrant Issued
DebtConversionConvertedInstrumentAmountWarrantIssued
199170 USD
cyrx Debt Conversion Converted Instrument Amount Warrant Issued
DebtConversionConvertedInstrumentAmountWarrantIssued
0 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt">Use of Estimates</font></i></strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> &#160;</font></i></strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from estimated amounts. The Company&#8217;s significant estimates include allowances for doubtful accounts and sales returns, recoverability of long-lived assets, deferred taxes and their accompanying valuations, valuation of derivative liabilities and valuation of common stock, warrants and stock options issued for products, services and conversion of debt.</font></div> <font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt"></font></div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> Concentrations of Credit Risk</font></i></strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt"> <strong><i><font style="FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> &#160;</font></i></strong></div> <div style="clear:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;LINE-HEIGHT: normal; TEXT-INDENT: 24.5pt; MARGIN: 0in 0in 0pt"> <font style="FONT-FAMILY: Times New Roman,serif; FONT-SIZE: 10pt"> The Company maintains its cash accounts in financial institutions. Accounts at these institutions are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) with basic deposit coverage limits up to $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">250,000</font> per owner. At September&#160;30, 2013 and March&#160;31, 2013, the Company had approximately&#160;$<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">278,000</font> and $<font style="FONT-FAMILY: 'Times New Roman','serif'; FONT-SIZE: 10pt">214,000</font>, respectively, of cash balances which exceeded the FDIC insurance limit. The Company performs ongoing evaluations of these institutions to limit its concentration risk exposure.</font></div> </div> <table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
cyrx Percentage Of Foreign Sales Revenue
PercentageOfForeignSalesRevenue
0.3 pure
cyrx Percentage Of Foreign Sales Revenue
PercentageOfForeignSalesRevenue
0.42 pure
CY2013Q3 cyrx Percentage Of Foreign Sales Revenue
PercentageOfForeignSalesRevenue
0.3 pure
CY2013Q3 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
0.29 pure
CY2012Q3 us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
0.1 pure
cyrx Maturity Period Of Highly Liquid Investments
MaturityPeriodOfHighlyLiquidInvestments
P90D
CY2013Q3 us-gaap Cash Fdic Insured Amount
CashFDICInsuredAmount
250000 USD
CY2013Q3 cyrx Cash Exceeds Fdic Insurance Limits
CashExceedsFdicInsuranceLimits
278000 USD
CY2013Q1 cyrx Cash Exceeds Fdic Insurance Limits
CashExceedsFdicInsuranceLimits
214000 USD
CY2013Q3 cyrx Foreign Sales Revenue Net
ForeignSalesRevenueNet
172000 USD
CY2012Q3 cyrx Foreign Sales Revenue Net
ForeignSalesRevenueNet
98000 USD
CY2012Q3 cyrx Percentage Of Foreign Sales Revenue
PercentageOfForeignSalesRevenue
0.42 pure
cyrx Foreign Sales Revenue Net
ForeignSalesRevenueNet
316000 USD
cyrx Foreign Sales Revenue Net
ForeignSalesRevenueNet
179000 USD
us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
0.3 pure
us-gaap Concentration Risk Percentage1
ConcentrationRiskPercentage1
0.11 pure
CY2013Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
34683 USD
CY2013Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
28533 USD
CY2013Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
8622 USD
CY2013Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
10679 USD
CY2013Q3 cyrx Property Plant And Equipment Percentage Of Specific Assets
PropertyPlantAndEquipmentPercentageOfSpecificAssets
0.89 pure
CY2013Q1 cyrx Property Plant And Equipment Percentage Of Specific Assets
PropertyPlantAndEquipmentPercentageOfSpecificAssets
0.87 pure
us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2013Q3 us-gaap Depreciation
Depreciation
61824 USD
us-gaap Depreciation
Depreciation
123544 USD
CY2012Q3 us-gaap Depreciation
Depreciation
92705 USD
us-gaap Depreciation
Depreciation
159546 USD
CY2013Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
27723 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
55446 USD
CY2012Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
29197 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
57385 USD
CY2013Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40523000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
39793000 shares
CY2012Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37761000 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
37779000 shares
CY2013Q3 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
603500 USD
CY2013Q1 us-gaap Due To Related Parties Current And Noncurrent
DueToRelatedPartiesCurrentAndNoncurrent
651500 USD
us-gaap Related Party Transaction Rate
RelatedPartyTransactionRate
0.06 pure
CY2006Q2 cyrx Aggregate Monthly Principal Payment
AggregateMonthlyPrincipalPayment
2500 USD
cyrx Increased In Monthly Principal Payment
IncreasedInMonthlyPrincipalPayment
2500 USD
CY2013Q3 cyrx Aggregate Principal Payment
AggregatePrincipalPayment
8000 USD
CY2013Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
9294 USD
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
18948 USD
CY2012Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
10744 USD
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
21838 USD
CY2013Q3 cyrx Accrued Interest Related Party
AccruedInterestRelatedParty
785112 USD
CY2013Q1 cyrx Accrued Interest Related Party
AccruedInterestRelatedParty
766164 USD
cyrx Maturity Period Of Remaining Unpaid Principal And Accrued Interest
MaturityPeriodOfRemainingUnpaidPrincipalAndAccruedInterest
2015-03-01
CY2013Q3 cyrx Maximum Amount Of Aggregate Monthly Principal Payment
MaximumAmountOfAggregateMonthlyPrincipalPayment
10000 USD
CY2012Q3 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
0 USD
CY2012Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
0 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
3091 USD
CY2013Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
3909801 USD
us-gaap Interest Expense Debt
InterestExpenseDebt
199170 USD
cyrx Debt Conversion Converted Instrument Units Issued
DebtConversionConvertedInstrumentUnitsIssued
19885874 shares
CY2013Q3 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
0.20
CY2013Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
0.37
cyrx Debt Conversion Converted Instrument Units Description
DebtConversionConvertedInstrumentUnitsDescription
Each Unit consisting of (i) one share of common stock of the Company (&#8220;Common Stock&#8221;) and (ii)&#160;one warrant to purchase one share of Common Stock at an exercise price of $0.37 per share.
us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2013 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2013Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
53000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
101000 USD
CY2012Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
49000 USD
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
107000 USD
cyrx Minimum Amount Of Additional Compensation
MinimumAmountOfAdditionalCompensation
2000000 USD
CY2013Q3 cyrx Consulting Service Fee
ConsultingServiceFee
118140 USD
cyrx Consulting Service Fee
ConsultingServiceFee
206451 USD
CY2012Q3 cyrx Consulting Service Fee
ConsultingServiceFee
96501 USD
cyrx Consulting Service Fee
ConsultingServiceFee
196671 USD
cyrx Period For Completion Of Agreement
PeriodForCompletionOfAgreement
P1Y
cyrx Automatically Renewal Period
AutomaticallyRenewalPeriod
P1Y
CY2013Q3 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0 USD
cyrx Additional Information For Additional Compensation
AdditionalInformationForAdditionalCompensation
additional compensation shall not be less than $2 million plus two times the &#8220;cost of work&#8221;
cyrx Number Of Installment To Discharge Additional Compensation
NumberOfInstallmentToDischargeAdditionalCompensation
3 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.37 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.66 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.27 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.24 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0184 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0222 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0019 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0063 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
CY2013Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
0.20
CY2013Q3 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
324882 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
7623272 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1564794 shares
CY2013Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1986913 USD
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y4M20D
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.27
CY2012Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3000000 shares
CY2013Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
7100000 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
1200000 shares
CY2012Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
30000 shares
CY2012Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
0.50
CY2011Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
155844 shares
CY2011Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
0.77
CY2011Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2500 shares
CY2011Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
1.38
CY2013Q3 cyrx Class Of Warrant Or Right Expense
ClassOfWarrantOrRightExpense
280 USD
cyrx Class Of Warrant Or Right Expense
ClassOfWarrantOrRightExpense
557 USD
CY2012Q2 cyrx Term Of Services Provided By Consultant
TermOfServicesProvidedByConsultant
P2Y
CY2011Q4 cyrx Term Of Services Provided By Consultant
TermOfServicesProvidedByConsultant
P5Y
CY2011Q2 cyrx Term Of Services Provided By Consultant
TermOfServicesProvidedByConsultant
P5Y
CY2012Q3 cyrx Class Of Warrant Or Right Expense
ClassOfWarrantOrRightExpense
280 USD
CY2013Q3 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
92171 USD
CY2013Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
500000 shares
CY2013Q2 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.20
CY2013Q2 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
100000 USD
CY2013Q3 cyrx Commission On Notes Issued Percentage
CommissionOnNotesIssuedPercentage
0.09 pure
CY2013Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1836245 shares
CY2013Q3 cyrx Fair Value Warrant Issued
FairValueWarrantIssued
760018 USD
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5408597 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
500000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
50000 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
12481869 shares
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4777115 shares
CY2013Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.93
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.20
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
8.40
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
0.53
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
0.89
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y10M13D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y6M25D
CY2013Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2452544 USD
CY2013Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
837971 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.24
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.39
CY2013Q4 cyrx Common Stock Exercise Per Unit
CommonStockExercisePerUnit
0.20
CY2013Q4 cyrx Conversion Of Outstanding Director Fees Into Securities
ConversionOfOutstandingDirectorFeesIntoSecurities
44556 USD

Files In Submission

Name View Source Status
0001144204-13-062580-index-headers.html Edgar Link pending
0001144204-13-062580-index.html Edgar Link pending
0001144204-13-062580.txt Edgar Link pending
0001144204-13-062580-xbrl.zip Edgar Link pending
cyrx-20130930.xml Edgar Link completed
cyrx-20130930.xsd Edgar Link pending
cyrx-20130930_cal.xml Edgar Link unprocessable
cyrx-20130930_def.xml Edgar Link unprocessable
cyrx-20130930_lab.xml Edgar Link unprocessable
cyrx-20130930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
image_002.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tlogo.jpg Edgar Link pending
v360047_10q.htm Edgar Link pending
v360047_ex10-31.htm Edgar Link pending
v360047_ex10-32.htm Edgar Link pending
v360047_ex31-1.htm Edgar Link pending
v360047_ex31-2.htm Edgar Link pending
v360047_ex32-1.htm Edgar Link pending
v360047_ex4-20.htm Edgar Link pending
v360047_ex4-21.htm Edgar Link pending
v360047_ex4-22.htm Edgar Link pending